60
Participants
Start Date
May 6, 2024
Primary Completion Date
April 6, 2028
Study Completion Date
May 6, 2028
PCSK9 inhibitor in combination with standard advanced first-line regimen group
Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
standard advanced first-line regimen group
Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
Guangdong Provincial People's Hospital
OTHER